Silo Pharma (NASDAQ:SILO) (NASDAQ:SILO) is a clinical-stage biotechnology company dedicated to discovering and developing novel therapeutics across oncology, neurology, women’s health and rare disease indications. The company applies an integrated approach that combines drug repurposing, de novo small‐molecule design and targeted delivery techniques. By leveraging proprietary bioinformatic tools and advanced chemical platforms, Silo Pharma seeks to accelerate the identification of promising candidates while reducing traditional attrition risks in drug development.
The company’s pipeline features multiple lead assets, including SPL-108, a peptide designed to inhibit tumor spread in high‐grade serous ovarian cancer, and SPL-123, an oral formulation being evaluated for major depressive disorder and generalized anxiety. Additional programs target central nervous system disorders and orphan disease states, with several preclinical initiatives advancing toward first‐in‐human studies. Silo Pharma has secured key licensing agreements and research collaborations with academic institutions and contract research organizations to bolster its translational efforts.
Headquartered in Boston, Massachusetts, Silo Pharma serves a global patient population through strategic partnerships and a growing clinical footprint. The company’s regulatory strategy includes expedited pathways where applicable, such as orphan drug designations and fast‐track status, to accelerate access to novel therapies. Manufacturing and scale-up activities are managed through a network of external providers, ensuring readiness for Phase 2 and Phase 3 studies across multiple regions.
Founded in 2017 by a team of seasoned biotech entrepreneurs and researchers, Silo Pharma is led by Chief Executive Officer Michael Levin. The leadership team brings deep expertise in pharmaceutical research, clinical development and regulatory affairs, supported by a board with extensive industry experience. Through its focused R&D strategy and commitment to innovation, Silo Pharma aims to deliver transformative treatments that address high‐unmet medical needs.
